世界のプロプロテインコンバターゼサブチリシン/ケキシン9型市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Proprotein Convertase Subtilisin/Kexin Type 9 Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A15073 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、102ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、プロプロテインコンバターゼサブチリシン/ケキシン9型のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。プロプロテインコンバターゼサブチリシン/ケキシン9型の種類別市場規模（SX-PCK9、O-304、K-312、BLSM-201、DCRPCSK-9、その他）、用途別市場規模（心血管疾患、同種家族性高コレステロール血症、肝疾患、メタボリックシンドローム、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・プロプロテインコンバターゼサブチリシン/ケキシン9型の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：AFFiRiS AG、Betagenon AB、Bioleaders Corp、BioLingus AG、Catabasis Pharmaceuticals Inc、Dicerna Pharmaceuticals Inc、Eli Lilly and Co、Ensemble Therapeutics Corp、Kowa Co Ltd、Novartis AG、Pfizer Inc、Regeneron Pharmaceuticals Inc、Serometrix LLC、Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd、The Medicines Company ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：SX-PCK9、O-304、K-312、BLSM-201、DCRPCSK-9、その他 ・用途別分析2016年-2026年：心血管疾患、同種家族性高コレステロール血症、肝疾患、メタボリックシンドローム、その他 ・プロプロテインコンバターゼサブチリシン/ケキシン9型の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・プロプロテインコンバターゼサブチリシン/ケキシン9型のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・プロプロテインコンバターゼサブチリシン/ケキシン9型のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・プロプロテインコンバターゼサブチリシン/ケキシン9型の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・プロプロテインコンバターゼサブチリシン/ケキシン9型の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Proprotein Convertase Subtilisin/Kexin Type 9 market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Proprotein Convertase Subtilisin/Kexin Type 9 size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Proprotein Convertase Subtilisin/Kexin Type 9 market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Proprotein Convertase Subtilisin/Kexin Type 9 market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
SX-PCK9
O-304
K-312
BLSM-201
DCRPCSK-9
Others

Market segment by Application, can be divided into
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others

Market segment by players, this report covers
AFFiRiS AG
Betagenon AB
Bioleaders Corp
BioLingus AG
Catabasis Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Ensemble Therapeutics Corp
Kowa Co Ltd
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Proprotein Convertase Subtilisin/Kexin Type 9 product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Proprotein Convertase Subtilisin/Kexin Type 9, with revenue, gross margin and global market share of Proprotein Convertase Subtilisin/Kexin Type 9 from 2019 to 2021.
Chapter 3, the Proprotein Convertase Subtilisin/Kexin Type 9 competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Proprotein Convertase Subtilisin/Kexin Type 9 market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Proprotein Convertase Subtilisin/Kexin Type 9 research findings and conclusion, appendix and data source.

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Proprotein Convertase Subtilisin/Kexin Type 9
1.2 Classification of Proprotein Convertase Subtilisin/Kexin Type 9 by Type
1.2.1 Overview: Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type in 2020
1.2.3 SX-PCK9
1.2.4 O-304
1.2.5 K-312
1.2.6 BLSM-201
1.2.7 DCRPCSK-9
1.2.8 Others
1.3 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market by Application
1.3.1 Overview: Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Cardiovascular Disease
1.3.3 Homozugous Familial Hyperchalesterolemia
1.3.4 Liver Disease
1.3.5 Metabolic Syndrome
1.3.6 Others
1.4 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size & Forecast
1.5 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast by Region
1.5.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region, (2016-2021)
1.5.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Prospect (2016-2026)
1.5.4 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Prospect (2016-2026)
1.5.6 South America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Proprotein Convertase Subtilisin/Kexin Type 9 Market Drivers
1.6.2 Proprotein Convertase Subtilisin/Kexin Type 9 Market Restraints
1.6.3 Proprotein Convertase Subtilisin/Kexin Type 9 Trends Analysis
2 Company Profiles
2.1 AFFiRiS AG
2.1.1 AFFiRiS AG Details
2.1.2 AFFiRiS AG Major Business
2.1.3 AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.1.4 AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AFFiRiS AG Recent Developments and Future Plans
2.2 Betagenon AB
2.2.1 Betagenon AB Details
2.2.2 Betagenon AB Major Business
2.2.3 Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.2.4 Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Betagenon AB Recent Developments and Future Plans
2.3 Bioleaders Corp
2.3.1 Bioleaders Corp Details
2.3.2 Bioleaders Corp Major Business
2.3.3 Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.3.4 Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bioleaders Corp Recent Developments and Future Plans
2.4 BioLingus AG
2.4.1 BioLingus AG Details
2.4.2 BioLingus AG Major Business
2.4.3 BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.4.4 BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 BioLingus AG Recent Developments and Future Plans
2.5 Catabasis Pharmaceuticals Inc
2.5.1 Catabasis Pharmaceuticals Inc Details
2.5.2 Catabasis Pharmaceuticals Inc Major Business
2.5.3 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.5.4 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Catabasis Pharmaceuticals Inc Recent Developments and Future Plans
2.6 Dicerna Pharmaceuticals Inc
2.6.1 Dicerna Pharmaceuticals Inc Details
2.6.2 Dicerna Pharmaceuticals Inc Major Business
2.6.3 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.6.4 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Dicerna Pharmaceuticals Inc Recent Developments and Future Plans
2.7 Eli Lilly and Co
2.7.1 Eli Lilly and Co Details
2.7.2 Eli Lilly and Co Major Business
2.7.3 Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.7.4 Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Eli Lilly and Co Recent Developments and Future Plans
2.8 Ensemble Therapeutics Corp
2.8.1 Ensemble Therapeutics Corp Details
2.8.2 Ensemble Therapeutics Corp Major Business
2.8.3 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.8.4 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Ensemble Therapeutics Corp Recent Developments and Future Plans
2.9 Kowa Co Ltd
2.9.1 Kowa Co Ltd Details
2.9.2 Kowa Co Ltd Major Business
2.9.3 Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.9.4 Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Kowa Co Ltd Recent Developments and Future Plans
2.10 Novartis AG
2.10.1 Novartis AG Details
2.10.2 Novartis AG Major Business
2.10.3 Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.10.4 Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Novartis AG Recent Developments and Future Plans
2.11 Pfizer Inc
2.11.1 Pfizer Inc Details
2.11.2 Pfizer Inc Major Business
2.11.3 Pfizer Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.11.4 Pfizer Inc Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Pfizer Inc Recent Developments and Future Plans
2.12 Regeneron Pharmaceuticals Inc
2.12.1 Regeneron Pharmaceuticals Inc Details
2.12.2 Regeneron Pharmaceuticals Inc Major Business
2.12.3 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.12.4 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Regeneron Pharmaceuticals Inc Recent Developments and Future Plans
2.13 Serometrix LLC
2.13.1 Serometrix LLC Details
2.13.2 Serometrix LLC Major Business
2.13.3 Serometrix LLC Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.13.4 Serometrix LLC Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Serometrix LLC Recent Developments and Future Plans
2.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
2.14.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Details
2.14.2 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Major Business
2.14.3 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.14.4 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Developments and Future Plans
2.15 The Medicines Company
2.15.1 The Medicines Company Details
2.15.2 The Medicines Company Major Business
2.15.3 The Medicines Company Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
2.15.4 The Medicines Company Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 The Medicines Company Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Proprotein Convertase Subtilisin/Kexin Type 9 Players Market Share
3.2.2 Top 10 Proprotein Convertase Subtilisin/Kexin Type 9 Players Market Share
3.2.3 Market Competition Trend
3.3 Proprotein Convertase Subtilisin/Kexin Type 9 Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Market Share by Type (2016-2021)
4.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Application (2016-2021)
5.2 Proprotein Convertase Subtilisin/Kexin Type 9 Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2026)
6.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2026)
6.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country
6.3.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2016-2026)
6.3.2 United States Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
6.3.3 Canada Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
6.3.4 Mexico Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2026)
7.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2026)
7.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country
7.3.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2016-2026)
7.3.2 Germany Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
7.3.3 France Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
7.3.5 Russia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
7.3.6 Italy Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2026)
8.2 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2026)
8.3 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region
8.3.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Region (2016-2026)
8.3.2 China Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
8.3.3 Japan Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
8.3.4 South Korea Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
8.3.5 India Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
8.3.7 Australia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2026)
9.2 South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2026)
9.3 South America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country
9.3.1 South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2016-2026)
9.3.2 Brazil Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
9.3.3 Argentina Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2026)
10.2 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2026)
10.3 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country
10.3.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2016-2026)
10.3.2 Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
10.3.4 UAE Proprotein Convertase Subtilisin/Kexin Type 9 Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million) by Region (2016-2021)
Table 5. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Region (2021-2026)
Table 6. AFFiRiS AG Corporate Information, Head Office, and Major Competitors
Table 7. AFFiRiS AG Major Business
Table 8. AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 9. AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Betagenon AB Corporate Information, Head Office, and Major Competitors
Table 11. Betagenon AB Major Business
Table 12. Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 13. Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bioleaders Corp Corporate Information, Head Office, and Major Competitors
Table 15. Bioleaders Corp Major Business
Table 16. Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 17. Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. BioLingus AG Corporate Information, Head Office, and Major Competitors
Table 19. BioLingus AG Major Business
Table 20. BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 21. BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Catabasis Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 23. Catabasis Pharmaceuticals Inc Major Business
Table 24. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 25. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Dicerna Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 27. Dicerna Pharmaceuticals Inc Major Business
Table 28. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 29. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Eli Lilly and Co Corporate Information, Head Office, and Major Competitors
Table 31. Eli Lilly and Co Major Business
Table 32. Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 33. Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Ensemble Therapeutics Corp Corporate Information, Head Office, and Major Competitors
Table 35. Ensemble Therapeutics Corp Major Business
Table 36. Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 37. Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Kowa Co Ltd Corporate Information, Head Office, and Major Competitors
Table 39. Kowa Co Ltd Major Business
Table 40. Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 41. Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 43. Novartis AG Major Business
Table 44. Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 45. Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Pfizer Inc Corporate Information, Head Office, and Major Competitors
Table 47. Pfizer Inc Major Business
Table 48. Pfizer Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 49. Pfizer Inc Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Regeneron Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors
Table 51. Regeneron Pharmaceuticals Inc Major Business
Table 52. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 53. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Serometrix LLC Corporate Information, Head Office, and Major Competitors
Table 55. Serometrix LLC Major Business
Table 56. Serometrix LLC Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 57. Serometrix LLC Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Corporate Information, Head Office, and Major Competitors
Table 59. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Major Business
Table 60. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 61. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. The Medicines Company Corporate Information, Head Office, and Major Competitors
Table 63. The Medicines Company Major Business
Table 64. The Medicines Company Proprotein Convertase Subtilisin/Kexin Type 9 Product and Solutions
Table 65. The Medicines Company Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million) by Players (2019-2021)
Table 67. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Share by Players (2019-2021)
Table 68. Breakdown of Proprotein Convertase Subtilisin/Kexin Type 9 by Company Type (Tier 1, Tier 2 and Tier 3)
Table 69. Proprotein Convertase Subtilisin/Kexin Type 9 Players Head Office, Products and Services Provided
Table 70. Proprotein Convertase Subtilisin/Kexin Type 9 Mergers & Acquisitions in the Past Five Years
Table 71. Proprotein Convertase Subtilisin/Kexin Type 9 New Entrants and Expansion Plans
Table 72. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million) by Type (2016-2021)
Table 73. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Share by Type (2016-2021)
Table 74. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Forecast by Type (2021-2026)
Table 75. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2021)
Table 76. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Forecast by Application (2021-2026)
Table 77. North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2021) & (USD Million)
Table 78. North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2021-2026) & (USD Million)
Table 79. North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2021) & (USD Million)
Table 80. North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2021-2026) & (USD Million)
Table 81. North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2016-2021) & (USD Million)
Table 82. North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2021-2026) & (USD Million)
Table 83. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2021) & (USD Million)
Table 84. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2021-2026) & (USD Million)
Table 85. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2021) & (USD Million)
Table 86. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2021-2026) & (USD Million)
Table 87. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2016-2021) & (USD Million)
Table 88. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2021-2026) & (USD Million)
Table 89. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2021) & (USD Million)
Table 90. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2021-2026) & (USD Million)
Table 91. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2021) & (USD Million)
Table 92. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2021-2026) & (USD Million)
Table 93. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Region (2016-2021) & (USD Million)
Table 94. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Region (2021-2026) & (USD Million)
Table 95. South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2021) & (USD Million)
Table 96. South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2021-2026) & (USD Million)
Table 97. South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2021) & (USD Million)
Table 98. South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2021-2026) & (USD Million)
Table 99. South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2016-2021) & (USD Million)
Table 100. South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2021-2026) & (USD Million)
Table 101. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2016-2021) & (USD Million)
Table 102. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Type (2021-2026) & (USD Million)
Table 103. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2016-2021) & (USD Million)
Table 104. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Application (2021-2026) & (USD Million)
Table 105. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2016-2021) & (USD Million)
Table 106. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Proprotein Convertase Subtilisin/Kexin Type 9 Picture
Figure 2. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type in 2020
Figure 3. SX-PCK9
Figure 4. O-304
Figure 5. K-312
Figure 6. BLSM-201
Figure 7. DCRPCSK-9
Figure 8. Others
Figure 9. Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Application in 2020
Figure 10. Cardiovascular Disease Picture
Figure 11. Homozugous Familial Hyperchalesterolemia Picture
Figure 12. Liver Disease Picture
Figure 13. Metabolic Syndrome Picture
Figure 14. Others Picture
Figure 15. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 16. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Forecast (2016-2026) & (USD Million)
Figure 17. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Region (2016-2026)
Figure 18. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Region in 2020
Figure 19. North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 21. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 22. South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 23. Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (USD Million) and Growth Rate (2016-2026)
Figure 24. Proprotein Convertase Subtilisin/Kexin Type 9 Market Drivers
Figure 25. Proprotein Convertase Subtilisin/Kexin Type 9 Market Restraints
Figure 26. Proprotein Convertase Subtilisin/Kexin Type 9 Market Trends
Figure 27. AFFiRiS AG Recent Developments and Future Plans
Figure 28. Betagenon AB Recent Developments and Future Plans
Figure 29. Bioleaders Corp Recent Developments and Future Plans
Figure 30. BioLingus AG Recent Developments and Future Plans
Figure 31. Catabasis Pharmaceuticals Inc Recent Developments and Future Plans
Figure 32. Dicerna Pharmaceuticals Inc Recent Developments and Future Plans
Figure 33. Eli Lilly and Co Recent Developments and Future Plans
Figure 34. Ensemble Therapeutics Corp Recent Developments and Future Plans
Figure 35. Kowa Co Ltd Recent Developments and Future Plans
Figure 36. Novartis AG Recent Developments and Future Plans
Figure 37. Pfizer Inc Recent Developments and Future Plans
Figure 38. Regeneron Pharmaceuticals Inc Recent Developments and Future Plans
Figure 39. Serometrix LLC Recent Developments and Future Plans
Figure 40. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Developments and Future Plans
Figure 41. The Medicines Company Recent Developments and Future Plans
Figure 42. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Share by Players in 2020
Figure 43. Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 44. Global Top 3 Players Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share in 2020
Figure 45. Global Top 10 Players Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share in 2020
Figure 46. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 47. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Share by Type in 2020
Figure 48. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share Forecast by Type (2021-2026)
Figure 49. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Share by Application in 2020
Figure 50. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share Forecast by Application (2021-2026)
Figure 51. North America Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Type (2016-2026)
Figure 52. North America Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Application (2016-2026)
Figure 53. North America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Country (2016-2026)
Figure 54. United States Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Canada Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Mexico Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Type (2016-2026)
Figure 58. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Application (2016-2026)
Figure 59. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Country (2016-2026)
Figure 60. Germany Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. France Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. United Kingdom Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Russia Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Italy Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Type (2016-2026)
Figure 66. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Application (2016-2026)
Figure 67. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Region (2016-2026)
Figure 68. China Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Japan Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. South Korea Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. India Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Australia Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. South America Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Type (2016-2026)
Figure 75. South America Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Application (2016-2026)
Figure 76. South America Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Country (2016-2026)
Figure 77. Brazil Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Argentina Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Type (2016-2026)
Figure 80. Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 Sales Market Share by Application (2016-2026)
Figure 81. Middle East and Africa Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Country (2016-2026)
Figure 82. Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 83. Saudi Arabia Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 84. UAE Proprotein Convertase Subtilisin/Kexin Type 9 Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 85. Methodology
Figure 86. Research Process and Data Source

---